Despite the fact that cardiovascular disease (CVD) is the number 1 cause of death globally, investment in drug development and new drug approvals for CVD are precipitously declining. In contrast, the trajectory of both investment in development as well as new drug approvals for oncology have been increasing steadily over the same time frame. The factors that have spurred drug development in oncology may be applicable to new efforts to overcome barriers to drug development for CVD. Greater investment in basic research and application of expedited regulatory pathways have contributed to a lowering of development barriers in oncology. Barriers in implementation are also critical. More rapid adoption of guideline-based therapies and lower access barriers by payers have contributed to fewer implementation barriers for oncology therapeutics. There is substantially greater advocacy among patients and physicians for new oncology therapeutics, and such advocacy efforts are likely to have had a meaningful impact on lowering barriers to develop new oncology therapeutics. Broad support of patient and physician advocacy efforts directed towards CVD may help overcome existing development and implementation barriers to new drug development, thereby spurring more Manuscript received January 17, 2019; accepted January 20, 2019. Illustration) . Rather than discussing all these reasons in detail, this paper will focus on the barriers that seem to have been lowered for oncology to suggest similar strategies that may be used to overcome barriers and increase investment in CVD.
Notwithstanding this potential for new therapies and great public health need, it is well recognized that over the past couple of decades there have been proportionally fewer CVD therapeutic candidates in all stages of drug development, including fewer new CVD drug approvals (3) (4) (5) (6) . Although substantial investments in large scale trials for CVD research continue, more investment seem to be shifting toward other therapeutic classes, such as oncology (3, 4) . CVD and oncology are the first and second leading causes of death, respectively, yet the investment trajectories are completely different. During the time that CVD drug approvals were declining, new drug approvals and investment in oncology increased significantly (3) (4) (5) (6) . Understanding the differences in trends and reasons for those differences may be informative and provide strategic insights into approaches used in oncology that can be applied in the treatment of CVD.
Several recent articles have thoroughly reviewed different reasons for the recent reduction in CVD drug development and compared it with the growing investment in oncology (3, 4, 7) . Many factors contribute to more uncertainty and a lower near-term return on investment for CVD relative to oncology. Some factors are related to aspects of drug development and regulatory approval whereas others are related to market dynamics once a drug has been approved. For clarity, this paper will group similar barriers together and refer to the former as development barriers and the latter as implementation barriers (Central Illustration). Rather than discussing all these reasons in detail, this paper will focus on the barriers that seem to have been lowered for oncology to suggest similar strategies that may be used to overcome barriers and increase investment in CVD.
DRUG APPROVAL TRENDS AND DEVELOPMENT BARRIERS
In the 1980s, approximately 1 in 4 approvals for all new drugs and biologics were in the CVD therapeutic class whereas w1 in 10 was in the oncology class (5).
In relative terms, in the 1980s U.S. Khakoo et al.
Overcoming CVD Drug Development Barriers There is a need to re-envision the development pathways for CVD drugs considering the public health importance of CVD. If this can be accomplished, it will help improve the return on investment and provide more incentive to invest in CVD and further improve public health.
IMPLEMENTATION BARRIERS
Another key factor in return on investment is how rapidly the innovation is adopted into clinical prac- The generation of novel cardiovascular therapeutics is impeded by a lack of investment due to barriers that limit investment in research in development as well as barriers that slow adoption of safe and effective therapies that limit their implementation. A "CVD Moonshot Program," consisting of elements that have fueled the rapid development of new cancer therapeutics-increased research funding, novel surrogate endpoints in clinical trials, expedited regulatory pathways, and government mandated coverage-could pave a road towards eradication of CVD. CVD ¼ cardiovascular disease.
Khakoo et al.
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Overcoming CVD Drug Development Barriers treatment guidelines, there seems to be clinical inertia regarding adherence to the guidelines. This may be due to the previous success in reducing morbidity and mortality which creates an impression that sufficient progress had been made and underestimates the true burden of CVD. Also, identifying patients at imminent risk of an event is difficult in clinical practice due to a lack of near-term risk prediction tools, particularly for asymptomatic patients (15) . Another issue may be that preventing future events is not considered a priority in a system that has a short-term budget view. The current structure of our health care system incentivizes treating conditions that have impact in the short run but does not provide sufficient incentive to prevent or treat conditions that could have enormous longterm impact (e.g., atherosclerotic CVD [ASCVD]).
Even with CV conditions that do have short-term impact and a strong immediate value proposition, such as heart failure (HF), adoption of new therapies is slow. Even though HF has mortality rates comparable to several common cancers (16) , when a drug in a new class of HF therapeutics, angiotensin receptor neprilysin inhibition (ARNI), showed a 20% reduction in CV death and similar or better tolerability compared with standard of care, only w2% of eligible patients were prescribed the drug 1 year after approval (17) . This was close to 2 years after the initial report of the benefit of ARNI (18) . An analysis by NBE ¼ new molecular entity; NME ¼ new molecular entity.
Overcoming CVD Drug Development Barriers A P R I L 2 0 1 9 : 2 6 9 -7 4 D drug benefit (25) . Although they are not subject to these government mandates for commercially insured patients, payers have been reluctant to impose meaningful restrictions on cancer therapies.
This reluctance may be related to previous backlash from advocacy groups when restrictions have been imposed in the past (25) .
OVERCOMING BARRIERS THROUGH STRONG ADVOCACY
A common thread in all the differences in oncology and CVD is the strong advocacy in oncology. Initiative (30) . If cardiologists champion these movements en masse, we will have great momentum.
Like they have in oncology, we need to have a CV
"moonshot" and we need to be advocates in the fight to eradicate CVD. 
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